NEJM: Local therapy of loferst cream can significantly improve skin symptoms in psoriasis patients.

Oral systemic phosphodiesterase inhibitors have a better efficacy in the treatment of psoriasis Recently researchers assessed the effectiveness of local treatment of psoriasis in Loforstette creamAdults with plaque-like psoriasis randomly used a continuous week per day with Afleuste cream, a Lofostcream cream, or a placebo creamThe study's main therapeutic outcome scoring week's skin scoring assessment was assessed based on plaque thickening, fouling, and erythema (the higher the score was severe) secondary results included skin scores and interjoint scoring improvement grade dandruff area and severity index () scoring changes (ranging from higher scores to indicate more serious illness)The patient participated in the study receiving the Loforst cream under the name of the Loforst cream and received the placebo creamThe scores were observed in patients in the first week of the Roforusst group, patients in the Rofost group, and patients in the placebo groupPatients who had mild interjoint psoriasis at baseline check-ups scored in the first week and the interjoint region scored at a grade-improved Roforst group for placeboThe baseline score for the Roforst group was the average change for the weekly and baseline of the group as a placebo group、? And?The frequency of reactions at the application site between groups is similarStudies have shown that loferste creams can significantly improve the symptoms of psoriasis patients